Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary) ; Antidepressants
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms PYXIS
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

  • 28 Aug 2023 Results of pooled analysis from (NCT01360645, NCT01360632, NCT02196506, and NCT01360866) assessing effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with MDD and prediabetes published in the Journal of Clinical Psychiatry
  • 19 Sep 2022 Results of post-hoc analysis (NCT01360645, NCT01360632, NCT02196506 & NCT01727726) assessing the effects of adjunctive brexpiprazole on different symptom clusters in major depressive disorder, published in the Journal of Affective Disorders.
  • 05 Oct 2021 Results of pooled and post hoc analysis from NCT01360645, NCT01360632, NCT02196506 assessing whether baseline level of functioning moderates the benefits of adjunctive brexpiprazole on life engagement, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top